Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus

Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic. The disease is caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), an RNA beta coronavirus phylogenetically similar to SARS coronavirus. To dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Centonze, Diego, Rocca, Maria A., Gasperini, Claudio, Kappos, Ludwig, Hartung, Hans-Peter, Magyari, Melinda, Oreja-Guevara, Celia, Trojano, Maria, Wiendl, Heinz, Filippi, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038920/
https://www.ncbi.nlm.nih.gov/pubmed/33844056
http://dx.doi.org/10.1007/s00415-021-10545-2
_version_ 1783677485522616320
author Centonze, Diego
Rocca, Maria A.
Gasperini, Claudio
Kappos, Ludwig
Hartung, Hans-Peter
Magyari, Melinda
Oreja-Guevara, Celia
Trojano, Maria
Wiendl, Heinz
Filippi, Massimo
author_facet Centonze, Diego
Rocca, Maria A.
Gasperini, Claudio
Kappos, Ludwig
Hartung, Hans-Peter
Magyari, Melinda
Oreja-Guevara, Celia
Trojano, Maria
Wiendl, Heinz
Filippi, Massimo
author_sort Centonze, Diego
collection PubMed
description Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic. The disease is caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), an RNA beta coronavirus phylogenetically similar to SARS coronavirus. To date, more than 132 million cases of COVID19 have been recorded in the world, of which over 2.8 million were fatal (https://coronavirus.jhu.edu/map.html). A huge vaccination campaign has started around the world since the end of 2020. The availability of vaccines has raised some concerns among neurologists regarding the safety and efficacy of vaccination in patients with multiple sclerosis (MS) taking immunomodulatory or immunosuppressive therapies.
format Online
Article
Text
id pubmed-8038920
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-80389202021-04-12 Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus Centonze, Diego Rocca, Maria A. Gasperini, Claudio Kappos, Ludwig Hartung, Hans-Peter Magyari, Melinda Oreja-Guevara, Celia Trojano, Maria Wiendl, Heinz Filippi, Massimo J Neurol Original Communication Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic. The disease is caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), an RNA beta coronavirus phylogenetically similar to SARS coronavirus. To date, more than 132 million cases of COVID19 have been recorded in the world, of which over 2.8 million were fatal (https://coronavirus.jhu.edu/map.html). A huge vaccination campaign has started around the world since the end of 2020. The availability of vaccines has raised some concerns among neurologists regarding the safety and efficacy of vaccination in patients with multiple sclerosis (MS) taking immunomodulatory or immunosuppressive therapies. Springer Berlin Heidelberg 2021-04-12 2021 /pmc/articles/PMC8038920/ /pubmed/33844056 http://dx.doi.org/10.1007/s00415-021-10545-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Communication
Centonze, Diego
Rocca, Maria A.
Gasperini, Claudio
Kappos, Ludwig
Hartung, Hans-Peter
Magyari, Melinda
Oreja-Guevara, Celia
Trojano, Maria
Wiendl, Heinz
Filippi, Massimo
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
title Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
title_full Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
title_fullStr Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
title_full_unstemmed Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
title_short Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
title_sort disease-modifying therapies and sars-cov-2 vaccination in multiple sclerosis: an expert consensus
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038920/
https://www.ncbi.nlm.nih.gov/pubmed/33844056
http://dx.doi.org/10.1007/s00415-021-10545-2
work_keys_str_mv AT centonzediego diseasemodifyingtherapiesandsarscov2vaccinationinmultiplesclerosisanexpertconsensus
AT roccamariaa diseasemodifyingtherapiesandsarscov2vaccinationinmultiplesclerosisanexpertconsensus
AT gasperiniclaudio diseasemodifyingtherapiesandsarscov2vaccinationinmultiplesclerosisanexpertconsensus
AT kapposludwig diseasemodifyingtherapiesandsarscov2vaccinationinmultiplesclerosisanexpertconsensus
AT hartunghanspeter diseasemodifyingtherapiesandsarscov2vaccinationinmultiplesclerosisanexpertconsensus
AT magyarimelinda diseasemodifyingtherapiesandsarscov2vaccinationinmultiplesclerosisanexpertconsensus
AT orejaguevaracelia diseasemodifyingtherapiesandsarscov2vaccinationinmultiplesclerosisanexpertconsensus
AT trojanomaria diseasemodifyingtherapiesandsarscov2vaccinationinmultiplesclerosisanexpertconsensus
AT wiendlheinz diseasemodifyingtherapiesandsarscov2vaccinationinmultiplesclerosisanexpertconsensus
AT filippimassimo diseasemodifyingtherapiesandsarscov2vaccinationinmultiplesclerosisanexpertconsensus

Ejemplares similares